Related Experiment Video

Updated: Jan 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

CD137L promotes immune surveillance in melanoma via HLTF regulation

Long Liang1,2, Lin Zhu1,3, Xin Li2

  • 1Department of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China.

Nature Communications
|September 26, 2025
PubMed

Insights

Boosting CD137L expression in melanoma cells enhances anti-tumor immunity and T cell survival. This finding supports combination therapies with immune checkpoint blockers (ICBs) for improved cancer treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Immune checkpoint blockers (ICBs) show efficacy in various cancers but benefit only a subset of patients.
  • Identifying novel therapeutic targets is crucial to improve ICB response rates.
  • Melanoma treatment with ICBs necessitates understanding mechanisms of resistance and response.

Purpose of the Study:

  • To identify novel therapeutic targets for enhancing ICB efficacy in melanoma.
  • To elucidate the role of CD137L in anti-tumor immunity and ICB response.
  • To explore combination strategies involving CD137L induction and ICBs.

Main Methods:

  • Integration of multi-omics data from melanoma patients treated with ICBs.
  • In vitro and in vivo functional assays to assess CD137L's impact on anti-tumor immunity.
  • Mechanistic studies to identify transcriptional regulators of CD137L.
  • Evaluation of AICAR as a therapeutic agent for CD137L induction.

Main Results:

  • A positive correlation was found between tumor CD137L expression and PD-1 blockade efficacy.
  • CD137L induction in cancer cells enhanced CD8+ T cell survival and anti-tumor immunity.
  • Helicase-like transcription factor (HLTF) was identified as a key regulator of CD137L expression.
  • AICAR, an AMPK agonist, induced CD137L and showed synergistic effects with PD-1 and CTLA-4 blockade.

Conclusions:

  • CD137L plays a critical role in enhancing anti-tumor immunity and ICB efficacy in melanoma.
  • HLTF-mediated regulation of CD137L offers a mechanistic insight into immune response modulation.
  • AICAR-mediated induction of CD137L represents a promising combination therapy strategy to improve melanoma treatment outcomes.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.8K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.5K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K